MGXライブシグナル | Getagraph.comで利益を最大化

売る 136556 min ago

@ $12.23

発行日: 15 2月 2024 @ 03:22

リターン: -42.76%

前回のシグナル: 2月 14 - 04:08

前回のシグナル: 買う

リターン: 5.43 %

Live Chart Being Loaded With Signals

Commentary (18 5月 2024 @ 05:00):

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States...

Stats
本日の出来高	52 467.00
平均出来高	132 130
時価総額	262.25M
次の収益日	( $0 ) 2024-06-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0140 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-08	Novo Holdings A/s	Sell	147 415	SERIES B PREFERRED STOCK
2024-02-08	Novo Holdings A/s	Sell	691 760	SERIES B-1 PREFERRED STOCK
2024-02-08	Noonberg Sarah B.	Sell	0	Common Stock
2024-02-08	Borges Luis	Buy	0

INSIDER POWER
-100.00
Last 3 transactions
Buy: 0 \| Sell: 839 175

ボリューム相関

長: 0.01 (neutral)

短: 0.11 (neutral)

Signal:(52.84) Neutral

Metagenomi, Inc. Common 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Metagenomi, Inc. Common 相関 - 通貨/商品

0.42
( neutral )

-0.28
( neutral )

0.00
( neutral )

0.18
( neutral )

0.30
( neutral )

Financial Reports:

No articles found.

Metagenomi, Inc. Common Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Metagenomi, Inc. Common

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.